|
|
□■ 発表論文 ■□
 2021年
Tachibana T
Allogeneic hematopoietic cell transplantation in patients with acute myeloid. J Clin Hematol. 2011,62(5):496-504
Tachibana T, Kanda J, Ishizaki T et al.
Pre‑conditioning intervention in patients with relapsed or refractory acute
lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation:
a KSGCT multicenter retrospective analysis. Annals of Hematology (2021)
100:2763–2771
Nakasone H, Kakp S, Tachibana R et al.
Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free
Survival. Transplantation and Cellular Therapy 27 (2021) 800.e1-800.e8
Tachibana T, Kanda J, Ishizaki T et al.
Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. TCT 27 (2021) 70.e1-70.e8
Kikuchi T, Mori T, Ohwada C, et al.
Pharmacokinetics of intravenous busulfan as condition for hematopoietic
stem cell transplantation: comparison between combinations with cyclophosphamide
and fludarabine. IJH (2021)113:123-133
2020年
Tachibana T, Kanda J, Ishizaki T et al.
Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. BBMT 26 (2020) 998-1004
2019年
Ohwada C, Sakaida E, Igarashi A, et al.
A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. BBMT 2020 Jan;26(1):162-170.
Kako S, Kanda Y, Onizuka M, et al.
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre‐transplant conditioning using fludarabine, reduced‐dose cyclophosphamide, and low‐dose thymoglobulin: A KSGCT prospective study. AJH https://doi.org/10.1002/ajh.25693
Tachibana T, Ishizaki T, Takahashi S, et al.
Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. BMT https://doi.org/10.1038/s41409-019-0689-8
Shimizu H, Doki N, Kanamori H, et al.
Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia
chromosome-negative ALL who underwent an allogeneic transplant. BMT 2019
Dec;54(12):2020-2026.
Tachibana T, Kanda J, Ishizaki T, et al.
Prognostic index for patients with relapsed or refractory acute myeloid
leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter
analysis. Leukemia. 2019 Nov;33(11):2610-2618.
Shimizu R, Takeuchi M, Sakaida E, et al.
Efficacy and safety of oral deferasirox treatment for transfusional iron
overload in pure red cell aplasia patients after allogeneic stem cell transplantation.
Ann Hematol. 2019 Jul;98(7):1781-1783.
2018年
Tachibana T, Kanda J, Machida S, et al.
Deferasirox for the treatment of iron overload after allogeneic hematopoietic
cell transplantation: multicenter phase I study (KSGCT1302) Int J Hematol.
2018 May;107(5):578-585.
Doki N, Kakihana K, Ashizawa M, et al.
Clinical characteristics of calcineurin inhibitor-induced pain syndrome (CIPS) after allogeneic hematopoietic stem cell transplantation
Jounal of Hematopoietic cell Transplantation Vol6. No.2 115-119
Motohashi K, Fujisawa S, Doki N, et al.
Cytogenetic risk stratification may predict allogeneic hematopoietic stem
cell transplantation outcomes for chronic myelomonocytic leukemia. Leuk
Lymphoma. 2018 Jun;59(6):1332-1337.
2017年
Kako S, Kanda Y, Kato J, et al.
The bridge treatment selected at the decision for transplantation did not
affect the outcomes in patients with MDS. Hematol Oncol 2017;35:341-349
2016年
Kanda Y, Kobayashi T, Mori T, et al.
A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplantation 2016 51, 103–109
2015年
Shimizu H, Saitoh T, Machida S, et al.
Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol. 2015;95:455–460.
Tanaka M, Kanamori H, Matsumoto K, et al.
Clinical significance of pretransplant serum ferritin on the outcome of
allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study
Group for Cell Therapy. Bone Marrow Transplant 2015;50:727-733.
Motohashi K, Fujisawa S, Onizuka M, et al.
Effect of the order of TBI and cyclophosphamide administration on the outcome
of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant
2015;50:1476-1479.
Yano S, Mori T, Kanda Y, et al.
Favorable survival after allogeneic stem cell transplantation with reduced-intensity
conditioning regimens for relapsed/refractory follicular lymphoma. Bone
Marrow Transplant 2015;50:1299-1305.
2014年
Nakaya A, Mori T, Tanaka M, et al.
Does the hematopoietic cell transplantation specific comorbidity index
(HCT-CI) predict transplantation outcomes? A prospective multicenter validation
study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant
2014;20:1553-1559.
2013年
Doki N, Miyawaki S, Tanaka M, et al.
Visceral varicella zoster virus infection after allogeneic stem cell transplantation.
Transpl Infect Dis. 2013;15:314-318.
Oshima K, Kanda Y, Nanya Y, et al.
Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation.. Ann Hematol. 2013;92:255-260.
Mori T, Tanaka M, Kobayashi T, et al.
Prospective Multicenter Study of Single-Unit Cord Blood Transplantation
with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic
Malignancies. Biol Blood Marrow Transplant 2013;19:486-491.
2012年
Shimizu H, Saitoh T, Tanaka M, et al.
Allogeneic hematopoietic stem cell transplantation for adult AML patients
with granulocytic sarcoma. Leukemia 2012;26:2469–2473.
Takeuchi M, Nakaseko C, Ohwada C, et al.
Allogeneic hematopoietic stem cell transplantation for primary and secondary
myelofibrosis: a retrospective, multicenter study of the Kanto Study Group
for Cell Therapy (KSGCT). Journal of Hematopoietic Cell Transplant 2012;1:15-23.
Yokota A, Ozawa S, Masanori T, et al.
Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone
Marrow Transplant 2012;47:95–100.
2011年
Sakai R, Kanamori H, Nakaseko C, et al.
Air-leak syndrome following allo-SCT in adult patients: report from the
Kanto Study Group for Cell Therapy in Japan. Bone Marrow Transplant 2011;46:379–384.
Nakaseko C, Ozawa S, Sakaida E, et al.
Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 2011;93:375–382.
2010年
Nakasone H, Kanda Y, Takasaki H, et al.
Prophylactic impact of imatinib administration after allogeneic stem cell
transplantation on the incidence and severity of chronic graft versus host
disease in patients with Philadelphia chromosome-positive leukemia. Leukemia
2010;24:1236-1239.
萩原真紀,金森平和,酒井美和,ほか
関東造血幹細胞移植共同研究グループにおける同種造血幹細胞移植後の生着不全に対する再移植の後方視的検討. 臨床血液 2010,51:390-397.
Hagihara M, Kanamori H, Sakai M, et al.
Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation ―A retrospective survey by Kanto Study Group for Cell Therapy. Jpn J Clin Hematol. 2010,51:390-397.
2009年
Oda K, Nakaseko C, Ozawa S, et al.
Fasciitis and myositis: an analysis of muscle-related complications caused
by chronic GVHD after allo-SCT. Bone Marrow Transplant 2009;43:159–167.
Nakasone H, Kanda Y, Ueda T, et al.
Retrospective comparison of mobilization methods for autologous stem cell
transplantation in multiple myeloma. Am J Hematol. 2009;84:809-814.
2008年
Oshima K, Kanda Y, Yamashita T, et al.
Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2008;14:1100-1107.
坂巻 壽
関東造血幹細胞移植共同研究グループのこれまでと将来. 臨床血液 2008;49:464-468.
2007年
藤巻克通,中世古知昭,大島久美,ほか
HBs抗体陽性患者における同種造血幹細胞移植後のB型肝炎ウイルスの再活性化. 臨床血液 2007;48:386-390.
Fujimaki K, Nakaseko C, Oshima K, et al.
Hepatitis B virus reactivation in patients with HBs antibodies after allogeneic hematopoietic stem cell transplantation. Jpn J Clin Hematol. 2007;48:386-390.
2006年
Kanda Y, Hyo R, Yamashita T, et al.
Effect of Blood Cyclosporine Concentration on the Outcome of Hematopoietic
Stem Cell Transplantation From an HLA-Matched Sibling Donor. Am J Hematol.
2006;81:838-844.
Fujimaki K, Mori T, Kida A, et al.
Human Herpesvirus 6 Meningoencephalitis in Allogeneic Hematopoietic Stem
Cell Transplant Recipients. Int J Hematol. 2006;84:432-437.
2003年
Nakajima H, Oki M, Kishi K, et al.
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide
for patients with hematologic malignancies. Cli Lab Haematol. 2003;25:383–391.
2002年
高田覚,岡本真一郎,坂巻壽,ほか
50歳以上の症例に対する同種造血幹細胞移植の検討. 臨床血液
2002;43:904-910.
Takada S, Okamoto S, Sakamaki H, et al.
Outcome of allogeneic stem cell transplantation in patients old than 50years
of age. Jpn J Clin Hematol. 2002;43:904-910.
2001年
藤巻克通,藤澤信,青墳信之,ほか
GVL効果の増強を目的とした免疫抑制剤の早期減量、中止のfeasibilityの検討. 臨床血液 2001;42:680-684.
Fujimaki K, Fujisawa S, Aotsuka N, et al.
Feasibility of early tapering and discontinuation of cyclosprine to intensify
thegraft-versus-leukemia effect in patients with advanced hematologic neoplasms.
Jpn J Clin Hematol. 2001;42:680-684.
2000年
Ohashi K, Tanabe J, Watanabe R, et al.
The Japanese Multicenter Open Randomized Trial of Ursodeoxycholic Acid
Prophylaxis for Hepatic Veno-Occlusive Disease After Stem Cell Transplantation.
Am J Hematol. 2000;64:32–38.
|
|
|
